Study found no evidence that cannabis terpenes interact with cannabinoid receptors | Research

The takeaway

In laboratory testing, five common cannabis terpenes showed no detectable activity at CB1 or CB2 receptors and did not modify the binding or function of THC, CBD, or the endocannabinoid 2-AG.

Cannabis researchers, consumers interested in the entourage effect, and those evaluating strain-specific claims.

Zero terpene-cannabinoid receptor interaction detected

The Backstory

In 2020, the entourage effect was the cannabis industry's favorite idea. Dispensaries marketed products by terpene profile. Consumers were told that myrcene meant couch lock, limonene meant uplift, and pinene meant clarity. Russo's 2011 review had mapped theoretical synergies between terpenes and cannabinoids. The underlying assumption was that terpenes modify the cannabis experience by interacting with the same cannabinoid receptors that THC and CBD target.

A team of pharmacologists at the University of Auckland decided to test that assumption directly. They put five common cannabis terpenes in a dish with CB1 and CB2 receptors and measured what happened.

Nothing happened.

The Experiment

This wasn't a review paper or a theoretical framework. It was a bench experiment — the kind of straightforward pharmacological test that should have been done years earlier.

How They Did It

Testing Terpenes at Cannabinoid Receptors

Express receptors

HEK293 cells were engineered to express human CB1 or CB2 receptors on their surface. These are clean systems — the only cannabinoid receptors present are the ones the researchers put there.

Standard in vitro pharmacology approach for receptor characterization

Select terpenes

Five of the most common cannabis terpenes were tested: myrcene, alpha-pinene, beta-pinene, beta-caryophyllene, and limonene. These are the terpenes most frequently cited in entourage effect discussions.

Tested individually and in mixtures

Radioligand binding

Used [3H]-CP55,940 (a radiolabeled cannabinoid) to measure whether terpenes affected binding at CB1 or CB2. This assay detects both orthosteric binding (competing for the same site) and allosteric modulation (changing the receptor's shape).

Sensitive enough to detect even subtle interactions

Functional assays

Measured whether terpenes activated CB1 or CB2 on their own, or modified the activation produced by THC, CBD, or the endocannabinoid 2-AG.

Tests both direct agonism and modulatory effects

Test combinations

Terpenes were tested alone and in combination with THC, CBD, and 2-AG to detect any synergistic or modulatory interaction.

If terpenes modify cannabinoid effects through these receptors, this is where it would show up

Finlay et al. (2020), Front Pharmacol 11:359

The Results

Zero

detectable terpene-cannabinoid receptor interactions. None of the five terpenes tested — alone or in mixtures — altered the binding of the radioligand at CB1 or CB2. None activated either receptor on their own. None modified the binding or functional effects of THC, CBD, or 2-AG. The single possible exception: a weak interaction of beta-caryophyllene with CB2, consistent with previous reports but not strong enough to be conclusive in this assay.

For context, THC produces robust, dose-dependent activation of CB1 in these same assays. The terpenes produced nothing.

Finlay et al. (2020), Front Pharmacol 11:359; PMID 32269529

The paper's conclusion was direct: "This study adds to the evidence that the putative entourage effect cannot be explained by direct effects at CB1 or CB2."

What This Does and Doesn't Mean

The debate

Terpenes and the Entourage Effect After Finlay 2020

What This Study Demonstrated

strong

Five major cannabis terpenes do not directly bind or activate CB1 receptors
They do not modify THC's binding or activation of CB1
They do not modify CBD's interaction with CB1 or CB2
They do not modify 2-AG's activation of CB1 or CB2
The entourage effect — if it exists — does not work through direct terpene activity at cannabinoid receptors
Beta-caryophyllene showed only weak CB2 interaction — much less than previously reported by Gertsch et al. (2008)

What This Study Did NOT Demonstrate

moderate

This does NOT prove the entourage effect doesn't exist
Terpenes have documented activity at other receptor systems: 5-HT1A (serotonin), TRPV1, GABA-A, PPARs, adenosine receptors
Terpenes could modify cannabinoid pharmacokinetics (absorption, metabolism, distribution) without touching cannabinoid receptors
In vitro conditions don't capture the full complexity of inhaling cannabis in a living human
LaVigne et al. (2021) later found terpenes DID produce cannabinoid-like effects in mice — via CB1 and adenosine A2a receptors
Only five terpenes were tested — cannabis contains over 200

Finlay et al. (2020); LaVigne et al. (2021), Sci Rep

This distinction matters enormously. The study killed one specific mechanism — terpenes acting directly at CB1/CB2 — but it did not kill the broader question of whether terpenes modify the cannabis experience. It's like proving that a car's paint color doesn't affect its engine performance. True, important, but it doesn't mean the car has no other features worth considering.

The Contradiction

One year later, LaVigne et al. (2021) published in Scientific Reports with results that seemed to directly contradict Finlay's findings. Four terpenes — alpha-humulene, geraniol, linalool, and beta-pinene — produced cannabinoid tetrad behaviors in mice (the standard test for cannabinoid activity: sedation, hypothermia, reduced pain, reduced movement). Some of these effects could be blocked by a CB1 antagonist.

Contradictory Findings

Finlay 2020 vs. LaVigne 2021

Finlay et al. (2020)

In vitro (cell cultures with isolated receptors)
Tested: myrcene, alpha-pinene, beta-pinene, caryophyllene, limonene
Method: radioligand binding + functional assays
Finding: NO terpene activity at CB1 or CB2
Conclusion: entourage effect not mediated through cannabinoid receptors

No receptor interaction detected

LaVigne et al. (2021)

In vivo (live mice) + in vitro
Tested: alpha-humulene, geraniol, linalool, beta-pinene
Method: cannabinoid tetrad behaviors + antagonist reversal
Finding: Terpenes produced cannabinoid-like effects, some blocked by CB1 antagonist
Conclusion: terpenes are cannabimimetic via CB1 and adenosine A2a

Cannabinoid-like effects observed

Finlay et al. (2020), Front Pharmacol; LaVigne et al. (2021), Sci Rep

How can both be right? Several possibilities:

Different terpenes tested. Finlay tested myrcene, pinene, caryophyllene, limonene. LaVigne tested humulene, geraniol, linalool, beta-pinene. Only beta-pinene appeared in both. Terpenes are not interchangeable.

In vitro vs. in vivo. Isolated receptor assays in cell cultures don't capture what happens in a living organism. Terpenes might need to be metabolized, cross the blood-brain barrier, or interact with complex receptor systems to produce effects.

Different concentrations. The concentrations and delivery methods differed substantially.

Adenosine A2a receptors. LaVigne identified adenosine A2a receptors — not CB1 or CB2 — as a key terpene target. Finlay didn't test A2a. The effects might be real but running through a different receptor entirely.

Neither study has been definitively replicated or refuted. The science is genuinely unresolved.

The Lesson for Consumers

Myth vs. Reality

✕Myth

Terpenes enhance THC's effects by acting on the same cannabinoid receptors.

✓Reality

This specific mechanism has been tested and found unsupported. Five major cannabis terpenes showed no activity at CB1 or CB2 receptors and did not modify THC, CBD, or 2-AG binding or function. If terpenes modify the cannabis experience — and they may — they do so through other receptor systems (serotonin, adenosine, TRPV1, GABA) or through pharmacokinetic effects (altering absorption, metabolism, or distribution of cannabinoids). The entourage effect, if real, works differently than most people assume.

The Evidence

Finlay et al. (2020): zero terpene activity at CB1/CB2 in radioligand binding and functional assays. Five terpenes tested individually and in mixtures with THC, CBD, and 2-AG.

Finlay et al. (2020), Front Pharmacol 11:359

This study is important because it forces honesty. The entourage effect can no longer be casually explained as "terpenes plus cannabinoids working together at cannabinoid receptors." The most intuitive mechanism doesn't hold up. If terpenes matter — and they may — the mechanism is more complex than the marketing suggests.

For a full exploration of what the evidence supports, see our article on the entourage effect. For what terpenes actually are and what we know about them, see terpenes explained.

Related Research

The Terpene Debate

This study challenges the most commonly cited mechanism for the entourage effect. These are the papers it directly engages with.

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

Russo (2011)

The review that proposed terpene-cannabinoid synergies — Finlay tested the receptor mechanism and found it unsupported

Terpenes/Terpenoids in Cannabis: Are They Important?

Hanuš & Hod (2020)

Published the same year — the analytical chemistry showing which terpenes are actually in cannabis

A tale of two cannabinoids: THC and CBD therapeutic rationale

Russo & Guy (2006)

THC-CBD synergy IS clinically confirmed — the terpene layer is what Finlay's study challenges

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids

Pertwee et al. (2008)

The cannabinoid receptor pharmacology that terpenes were hypothesized to modify

Does this mean the entourage effect isn't real?

No. This study tested one specific mechanism — terpenes acting directly at cannabinoid receptors — and found it unsupported. The entourage effect could still operate through other mechanisms: terpenes acting at serotonin, adenosine, or GABA receptors; terpenes modifying how cannabinoids are absorbed or metabolized; or THC-CBD synergy (which is clinically confirmed and doesn't depend on terpenes at all). The study narrows the possible mechanisms but doesn't eliminate the concept.

What about the study that found terpenes DO have cannabinoid effects?

LaVigne et al. (2021) found that several terpenes produced cannabinoid-like behaviors in mice, some of which could be blocked by a CB1 receptor antagonist. However, the effects appeared to involve adenosine A2a receptors as well, and the two studies tested different terpenes using different methods. The contradiction is genuine and unresolved. This is science working in real time — conflicting results that haven't been reconciled yet.

Should I stop paying attention to terpene profiles?

Terpene profiles still tell you about aroma and flavor — that relationship is well-established. What this study challenges is the specific claim that terpenes modify your cannabis experience by acting at CB1 or CB2 receptors. Other terpene effects (through non-cannabinoid receptors) remain possible. The practical advice hasn't changed much: THC/CBD content and ratio are your best predictors of effect. Terpene profiles are a secondary consideration that may help you identify products you enjoy, even if the mechanism isn't what you were told.

What the researchers found

None of the five terpenes tested (myrcene, alpha-pinene, beta-pinene, beta-caryophyllene, and limonene) showed direct interactions with CB1 or CB2 receptors, either alone or in mixtures. They did not alter the binding of THC or CBD. A weak interaction of beta-caryophyllene with CB2 was the only possible exception.

Why it matters

This study provides direct evidence against one proposed mechanism for the entourage effect, specifically that terpenes enhance cannabinoid activity by interacting with cannabinoid receptors.

The numbers in context

Five terpenes tested: myrcene, alpha-pinene, beta-pinene, beta-caryophyllene, and limonene. None altered [3H]-CP55,940 binding or the binding/function of THC, CBD, or 2-AG at CB1 or CB2.

How the study worked

In vitro study using human CB1 and CB2 receptors expressed in HEK293 cells. Radioligand binding assays tested for orthosteric and allosteric interactions. Functional assays measured receptor activation.

What this study cannot tell us

In vitro study that cannot capture the full complexity of in vivo pharmacology. Terpenes may interact with other receptor systems not tested. The concentrations used may not reflect those achieved through cannabis consumption.

How to read the evidence

Moderate: well-designed in vitro study with multiple assay types, though limited by in vitro conditions.

When this study was published

Published in 2020 in Frontiers in Pharmacology.

The bigger picture

While this does not disprove the entourage effect entirely (terpenes may work through other receptors), it eliminates one of the most commonly cited mechanisms. The entourage effect, if it exists, likely operates through non-cannabinoid receptor pathways.

Questions still open

If terpenes do not act through cannabinoid receptors, what other mechanisms could explain reported differences between cannabis strains? Could terpenes affect cannabinoid pharmacokinetics rather than pharmacodynamics?

Common questions

Does this mean the entourage effect is not real?

Not necessarily. It means terpenes likely do not produce an entourage effect by acting directly at cannabinoid receptors. They might still influence cannabis effects through other receptor systems, drug metabolism, or blood-brain barrier penetration.

What about beta-caryophyllene at CB2?

There was a possible weak interaction, but it was not strong enough to be conclusive. Previous studies have suggested beta-caryophyllene may act as a CB2 agonist, but this study found only minimal evidence for that.

Read the original research

Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors.

Frontiers in pharmacology, 11, 359

View on PubMed ↗Publisher’s paper ↗

Citation

Finlay, David B; Sircombe, Kathleen J; Nimick, Mhairi; Jones, Callum; Glass, Michelle. (2020). Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors.. Frontiers in pharmacology, 11, 359. https://doi.org/10.3389/fphar.2020.00359